Myocardial fibrosis: biomedical research from bench to bedside

Myocardial fibrosis refers to a variety of quantitative and qualitative changes in the interstitial myocardial collagen network that occur in response to cardiac ischaemic insults, systemic diseases, drugs, or any other harmful stimulus affecting the circulatory system or the heart itself. Myocardia...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of heart failure Vol. 19; no. 2; pp. 177 - 191
Main Authors Gyöngyösi, Mariann, Winkler, Johannes, Ramos, Isbaal, Do, Quoc‐Tuan, Firat, Hüseyin, McDonald, Kenneth, González, Arantxa, Thum, Thomas, Díez, Javier, Jaisser, Frédéric, Pizard, Anne, Zannad, Faiez
Format Journal Article
LanguageEnglish
Published Oxford, UK John Wiley & Sons, Ltd 01.02.2017
Subjects
Animal models
Animals
Biomarkers
Biomedical Research
Cardiac imaging
Fibrosis
Heart Failure - diagnostic imaging
Heart Failure - drug therapy
Heart Failure - metabolism
Heart Failure - pathology
Humans
Myocardial fibrosis
Myocardium - pathology
Review
Reviews
Translational Medical Research
Biomarkers
Animal models
Myocardial fibrosis
Cardiac imaging
Online AccessGet full text

Cover

More Information
Summary:Myocardial fibrosis refers to a variety of quantitative and qualitative changes in the interstitial myocardial collagen network that occur in response to cardiac ischaemic insults, systemic diseases, drugs, or any other harmful stimulus affecting the circulatory system or the heart itself. Myocardial fibrosis alters the architecture of the myocardium, facilitating the development of cardiac dysfunction, also inducing arrhythmias, influencing the clinical course and outcome of heart failure patients. Focusing on myocardial fibrosis may potentially improve patient care through the targeted diagnosis and treatment of emerging fibrotic pathways. The European Commission funded the FIBROTARGETS consortium as a multinational academic and industrial consortium with the primary aim of performing a systematic and collaborative search of targets of myocardial fibrosis, and then translating these mechanisms into individualized diagnostic tools and specific therapeutic pharmacological options for heart failure. This review focuses on those methodological and technological aspects considered and developed by the consortium to facilitate the transfer of the new mechanistic knowledge on myocardial fibrosis into potential biomedical applications.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1388-9842
1879-0844
DOI:10.1002/ejhf.696